| Multiple Sclerosis |
1 |
1 |
| Drug Interaction |
0 |
0.99 |
| Artificial Intelligence |
0 |
0.7 |
| Healthcare and Medical Technology |
0 |
0.65 |
| Adverse Effects |
0 |
0.21 |
| Biologic Therapy |
0 |
0.18 |
| Patient Safety |
0 |
0.18 |
| Tyrosine Kinase Inhibitor |
0 |
0.1 |
| Antihypertensive Agents |
0 |
0.07 |
| Bradycardia |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Diet |
0 |
0.07 |
| Disease-Modifying Therapy |
0 |
0.07 |
| Immunomodulator |
0 |
0.07 |
| Metabolism |
0 |
0.07 |
| Multiple Sclerosis Treatment |
0 |
0.07 |
| Pharmacodynamics |
0 |
0.07 |
| Pharmacokinetics |
0 |
0.07 |
| Precision Medicine |
0 |
0.07 |
| Tyrosine Kinase |
0 |
0.07 |
| Arrhythmia |
0 |
0.06 |
| Genomic Medicine |
0 |
0.06 |
| Hypertension |
0 |
0.06 |